<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536170</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00076988</org_study_id>
    <secondary_id>FD-R-004814</secondary_id>
    <nct_id>NCT02536170</nct_id>
  </id_info>
  <brief_title>Arginine Therapy for Sickle Cell Disease Pain</brief_title>
  <official_title>Phase 2 Randomized Control Trial of Arginine Therapy for Pediatric Sickle Cell Disease Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Healthcare of Atlanta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether giving extra arginine, a simple amino acid, to
      patients with sickle cell disease seeking treatment for a pain crisis (vaso-occlusive painful
      events (VOE) will decrease pain scores, decrease the need for pain medications or decrease
      length of hospital stay or emergency department visit. Funding Source - FDA OOPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the effects of IV L-arginine hydrochloride therapy
      in children with sickle cell disease (SCD) and vaso-occlusive pain events (VOE).
      Specifically, the impact on total opioid use (mg/kg) over the duration of their emergency
      department (ED) visit and hospital stay will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total parenteral opioid use</measure>
    <time_frame>Post study drug delivery (Up to 8 hours)</time_frame>
    <description>The total amount of parenteral opioids used by participants measured in mg/kg. The total is calculated after study drug delivery for participants in the emergency department (ED) and during hospital stay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Discharge (Up to 7 days)</time_frame>
    <description>The total number of hours spent in the hospital from study drug delivery to time of discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to vaso-occlusive pain event (VOE) resolution in emergency department</measure>
    <time_frame>Post study drug delivery (Up to 8 hours)</time_frame>
    <description>The total number of hours between study drug delivery and the last parenteral opioid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to vaso-occlusive pain event (VOE) resolution in hospital</measure>
    <time_frame>Post study drug delivery (Up to 8 hours)</time_frame>
    <description>The total number of hours between study drug delivery and time of last parenteral opioid use, pain relief improved to tolerate oral pain medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vaso-occlusive pain (VOE) scores</measure>
    <time_frame>Baseline, Time of discharge (Up to 7 days)</time_frame>
    <description>Pain associated with VOE will be measured on a scale of 0-10, with the ends representing the extreme limits of &quot;no-pain&quot; (0) and &quot;worst pain&quot; (10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of emergency department (ED) stay</measure>
    <time_frame>Up to 8 hours</time_frame>
    <description>Total hours from time of ED triage to ED discharge or hospital admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Emergency Department (ED) discharge</measure>
    <time_frame>Post emergency department admission (Up to 8 hours)</time_frame>
    <description>Number of participants discharged from ED without a hospital ward admission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total opioid dose</measure>
    <time_frame>Post study drug delivery (Up to 8 hours)</time_frame>
    <description>Total opioid dose in mg/kg in the first 8 hours after study drug delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of study drug doses</measure>
    <time_frame>Duration of study (Up to 7 days)</time_frame>
    <description>The total number of study drug doses given throughout the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute chest syndrome</measure>
    <time_frame>Duration of study (Up to 7 days)</time_frame>
    <description>Number of participants who develop acute chest syndrome (not diagnosed priort to study drug delivery) throughout the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of blood transfusion</measure>
    <time_frame>Duration of study (Up to 7 days)</time_frame>
    <description>Number of participants requiring a blood transfusion throughout the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation level</measure>
    <time_frame>Discharge from emergency department (ED) (Up to 8 hours)</time_frame>
    <description>Average oxygen saturation level of participants at time of ED discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in oxygen saturation level</measure>
    <time_frame>Hospital admission (Up to 4 hours), Hospital discharge (Up to 7 days)</time_frame>
    <description>The difference in oxygen saturation levels from hospital admission to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of return visits to emergency department (ED) within 72 hours</measure>
    <time_frame>Post hospital discharge (within 72 hours)</time_frame>
    <description>Number of ED visits from patients who have been discharged within the previous 72 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospital re-admissions within 72 hours</measure>
    <time_frame>Post hospital discharge (within 72 hours)</time_frame>
    <description>Number of patients readmitted to the hospital within 72 hours of discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of return visits to emergency department (ED) within 30 days</measure>
    <time_frame>Post hospital discharge (within 30 days)</time_frame>
    <description>Number of ED visits from patients who have been discharged within the previous 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospital re-admissions with 30 days</measure>
    <time_frame>Post hospital discharge (within 30 days)</time_frame>
    <description>Number of patients readmitted to the hospital within 30 days of discharge.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Vaso-occlusive Pain Episode</condition>
  <arm_group>
    <arm_group_label>L-Arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive an intravenous (IV) infusion of L-arginine (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loading Dose and L-Arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive an intravenous (IV) infusion of one-time loading dose of L-arginine (200 mg/kg) followed by standard dose (100 mg/kg) three times a day until time of discharge from the emergency department (ED) or hospital.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive an intravenous (IV) infusion of placebo (normal saline 1-2 ml/kg) three times a day until time of discharge from the emergency department (ED) or hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine</intervention_name>
    <description>L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.</description>
    <arm_group_label>L-Arginine</arm_group_label>
    <arm_group_label>Loading Dose and L-Arginine</arm_group_label>
    <other_name>Arginine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine Loading Dose</intervention_name>
    <description>One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg</description>
    <arm_group_label>Loading Dose and L-Arginine</arm_group_label>
    <other_name>Arginine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of sickle cell disease (SCD); all genotypes

          -  Pain requiring medical care in an acute care setting (such as the emergency department
             or ED, hospital ward, day hospital, clinic) not attributable to non-sickle cell
             causes, that is moderate-to-severe requiring parenteral opioids

        Exclusion Criteria:

          -  Decision to discharge home from the acute care setting

          -  Hemoglobin less than 5 gm/dL or immediate need for red cell transfusion anticipated
             within next 12 hours

          -  Hepatic dysfunction of SGPT greater than 3 times the upper value

          -  Renal dysfunction of creatinine greater than 1.0

          -  Mental status or neurological changes

          -  Acute stroke or clinical concern for stroke

          -  Pregnancy

          -  Allergy to arginine

          -  Two (2) or more ED visits for VOE within the last 7 days prior to CURRENT ED visit

          -  Hospitalization within 14 days

          -  Previous randomization in this arginine RCT (patient consented and screen failed
             before receiving study drug or placebo remains eligible for future participation).

          -  Use of inhaled nitric oxide, sildenafil or arginine within the last month

          -  PICU admission from the emergency department

          -  Hypotension requiring treatment with clinical intervention

          -  Acidosis with Co2â‰¤ 16

          -  Newly started on HU for &lt;3 months

          -  Not an appropriate candidate in the investigator's judgment

          -  Patient refusal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Morris, MD</last_name>
    <phone>404-727-5500</phone>
    <email>claudia.r.morris@emory.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Zmitrovich, MS</last_name>
    <phone>404-785-7135</phone>
    <email>april.zmitrovich@choa.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Hugh Spalding</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Morris, MD</last_name>
      <phone>404-727-5500</phone>
      <email>claudia.r.morris@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Claudia Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Egleston</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Morris, MD</last_name>
      <phone>404-727-5500</phone>
      <email>claudia.r.morris@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Claudia Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta at Scottish Rite</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Morris, MD</last_name>
      <phone>404-727-5500</phone>
      <email>claudia.r.morris@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Claudia Morris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Claudia Morris</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Arginine Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

